GPRC5D Targeted CAR T Cells

Example 6

As shown in FIG. 10, GPRC5D 28z CAR8 lysed human MM cell lines L363, NCL-H929, and U266, compared to irrelevantly targeted 4h11-28z MUC16 targeted CAR T cells. The cytotoxicity exhibited by observed GPRC5D 28z CAR8 was specific to GPRC5D, as it did not lyse GPRC5D negative CD19 positive Raji Burkett lymphoma cell line, as shown in FIG. 10.

Free full text: Click here

US11866478B2. Nucleic acid molecules encoding chimeric antigen receptors targeting G-protein coupled receptor (2024-01-09). MEMORIAL SLOAN KETTERING CANCER CENTER [US], EUREKA THERAPEUTICS, INC. [US]. Inventors: Renier J. Brentjens [US], Eric L Smith [US], Cheng Liu [US].

Patent 2024

Cell line Cytotoxicity Gprc5d Human Lymphoma T cells

Top 5 similar protocols

Variable analysis

independent variables

GPRC5D 28z CAR8
Irrelevantly targeted 4h11-28z MUC16 targeted CAR T cells

dependent variables

Cytotoxicity toward human MM cell lines L363, NCL-H929, and U266
Cytotoxicity toward GPRC5D negative CD19 positive Raji Burkett lymphoma cell line

control variables

Positive control: GPRC5D 28z CAR8 T cells
Negative control: Irrelevantly targeted 4h11-28z MUC16 targeted CAR T cells

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!